Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia.

Clinical hemorheology and microcirculation - 1 Jan 2023

Aswad Mohamed Hussam, Kissova Jarmila, Ovesna Petra, Říhová Lucie, Penka Miroslav

Abstract excerpt

The clinical course of essential thrombocythemia (ET) is complicated with thrombosis which significantly impacts patients' mortality. Studies have identified JAK2V617F mutation as an independent risk factor for thrombosis. Circulating extracellular vesicles (EVs) were evaluated in several studies regarding myeloproliferative neoplasms and thrombosis as potential biomarkers. The present study investigates the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Platelets
Share to Janus Kinase 2
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Share to Thrombocythemia, Essential

Share to Thrombosis

Source

Identifiers

PMID: 37334581
DOI: 10.3233/CH-221678

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2V617F mutation and circulating extracellular vesicles in essential thrombocythemia.PMID 37334581Read ↗

The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.Semantic proximity Read ↗

JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.Semantic proximity Read ↗

The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.Semantic proximity Read ↗

Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia.Semantic proximity Read ↗

New advances in the pathogenesis and therapy of essential thrombocythemia.Semantic proximity Read ↗

Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia.Semantic proximity Read ↗

JAK2 mutation-related disease and thrombosis.Semantic proximity Read ↗

Essential thrombocythemia.Semantic proximity Read ↗

Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: a multicenter study from Korea.Semantic proximity Read ↗

Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.Semantic proximity Read ↗

Microparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemiaSemantic proximity Read ↗

The new WHO classification for essential thrombocythemia calls for revision of available evidences.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.